Tyrosine kinase inhibitors

Agus, 2002, Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth, Cancer Cell, 2, 127, 10.1016/S1535-6108(02)00097-1 Albanell, 2002, Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients, J. Clin. Oncol., 20, 110, 10.1200/JCO.20.1.110 Antonyak, 1998, Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor, J. Biol. Chem., 273, 2817, 10.1074/jbc.273.5.2817 Apperley, 2002, Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor β, N. Engl. J. Med., 347, 481, 10.1056/NEJMoa020150 Assersohn, 2003, Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer, Breast Cancer Res. Treat., 82, 113, 10.1023/B:BREA.0000003968.45511.3f Bardelli, 2003, Mutational analysis of the tyrosine kinome in colorectal cancers, Science, 300, 949, 10.1126/science.1082596 Baselga, 2002, Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types, J. Clin. Oncol., 20, 4292, 10.1200/JCO.2002.03.100 Basso, 2002, Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2, Oncogene, 21, 1159, 10.1038/sj.onc.1205184 Baum, 2002, Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer, Lancet, 359, 2131, 10.1016/S0140-6736(02)09088-8 Blume-Jensen, 2001, Oncogenic kinase signalling, Nature, 411, 355, 10.1038/35077225 Boulay, 2004, Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells, Cancer Res., 64, 252, 10.1158/0008-5472.CAN-3554-2 Buchdunger, 2000, Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors, J. Pharmacol. Exp. Ther., 295, 139 Cobleigh, 1999, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J. Clin. Oncol., 17, 2639, 10.1200/JCO.1999.17.9.2639 Cools, 2003, A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome, N. Engl. J. Med., 348, 1201, 10.1056/NEJMoa025217 Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Druker, 2001, Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome, N. Engl. J. Med., 344, 1038, 10.1056/NEJM200104053441402 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N. Engl. J. Med., 344, 1031, 10.1056/NEJM200104053441401 Fan, 1994, Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells, J. Biol. Chem., 269, 27595, 10.1016/S0021-9258(18)47026-3 Fukuoka, 2003, A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (THE IDEAL 1 Trial), J. Clin. Oncol., 21, 2237, 10.1200/JCO.2003.10.038 George, 2003, The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer, N. Engl. J. Med., 349, 419, 10.1056/NEJMp030061 Giaccone, 2004, Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer, J. Clin. Oncol., 22, 777, 10.1200/JCO.2004.08.001 Glockner, 2001, Amplification of growth regulatory genes in intraductal breast cancer is associated with higher nuclear grade but not with the progression to invasiveness, Lab. Invest., 81, 565, 10.1038/labinvest.3780265 Gorre, 2001, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification, Science, 293, 876, 10.1126/science.1062538 Gorre, 2002, BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90, Blood, 100, 3041, 10.1182/blood-2002-05-1361 Heinrich, 2003, Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor, J. Clin. Oncol., 21, 4342, 10.1200/JCO.2003.04.190 Heinrich, 2003, PDGFRA activating mutations in gastrointestinal stromal tumors, Science, 299, 708, 10.1126/science.1079666 Herbst, 2004, Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer, J. Clin. Oncol., 22, 785, 10.1200/JCO.2004.07.215 Huron, 2003, A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants, Clin. Cancer Res., 9, 1267 Kris, 2003, Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer, JAMA, 290, 2149, 10.1001/jama.290.16.2149 Lewis, 1993, Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies, Cancer Immunol. Immunother., 37, 255, 10.1007/BF01518520 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib, N. Engl. J. Med., 350, 2129, 10.1056/NEJMoa040938 Majumder, P.K., Febbo, P.G., Bikoff, R., Berger, R., Xue, Q., McMahon, L.M., Manola, J., Brugarolas, J., McDonnell, T.J., Golub, T.R., et al. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia via regulation of apoptotic and Hif1-dependent pathways. Nat. Med. Published online May 23, 2004. 10.1038/nm1052. Morgan, 2003, J. Clin. Oncol., 21, 3955, 10.1200/JCO.2003.08.092 Nagar, 2002, Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571), Cancer Res., 62, 4236 Nakao, 1996, Internal tandem duplication of the flt3 gene found in acute myeloid leukemia, Leukemia, 10, 1911 Neshat, 2001, Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR, Proc. Natl. Acad. Sci. USA, 98, 10314, 10.1073/pnas.171076798 Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., et al. (2004). EGFR mutations in lung cancer: Correlation with clinical response to Gefitinib therapy. Science. Published online April 29, 2004. 10.1126/science.1099314. Perez-Soler, 2003, Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?, Oncology, 17, 23 Ross, 1998, The HER-2/neu oncogene in breast cancer, Stem Cells, 16, 413, 10.1002/stem.160413 Rubin, 2002, Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans, J. Clin. Oncol., 20, 3586, 10.1200/JCO.2002.01.027 Rusnak, 2001, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo, Mol. Cancer Ther., 1, 85 Samuels, 2004, High frequency of mutations of the PIK3CA gene in human cancers, Science, 304, 554, 10.1126/science.1096502 Sawyers, 2003, Opportunities and challenges in the development of kinase inhibitor therapy for cancer, Genes Dev., 17, 2998, 10.1101/gad.1152403 Shah, 2002, Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia, Cancer Cell, 2, 117, 10.1016/S1535-6108(02)00096-X Slamon, 1989, Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science, 244, 707, 10.1126/science.2470152 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101 Vivanco, 2002, The phosphatidylinositol 3-Kinase AKT pathway in human cancer, Nat. Rev. Cancer, 2, 489, 10.1038/nrc839 Vogel, 2002, Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, J. Clin. Oncol., 20, 719, 10.1200/JCO.20.3.719 Yakes, 2002, Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action, Cancer Res., 62, 4132 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N. Engl. J. Med., 349, 427, 10.1056/NEJMoa021491 Yarden, 2001, Untangling the ErbB signalling network, Nat. Rev. Mol. Cell Biol., 2, 127, 10.1038/35052073